Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down - Here's What Happened

Key Points

• Agios Pharmaceuticals shares fell sharply, opening at $31.43 versus a prior close of $37.23, after the FDA extended its review of mitapivat for sickle cell disease.
• The FDA set a new PDUFA decision date of February 1, 2027, three months later than originally planned, while requesting additional information on whether a liver-safety Risk Evaluation and Mitigation Strategy is needed.
• Agios said additional safety data showed no comparable cases of serious liver injury in sickle cell patients, and analysts remain broadly positive with a consensus “Moderate Buy” rating and average price target of $41.50.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) shares gapped down prior to trading on Friday. The stock had previously closed at $37.23, but opened at $31.43. Agios Pharmaceuticals shares last traded at $31.5940, with a volume of 528,339 shares trading hands.

Key Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Mitapivat’s application received Priority Review and was submitted under the FDA’s accelerated approval pathway, reflecting the significant unmet need in sickle cell disease. Agios said it remains launch-ready and is continuing labeling discussions with the FDA. Agios FDA update
• Positive Sentiment: Agios reported that approximately nine months of additional safety data showed no cases of hepatocellular injury in sickle cell disease patients with a pattern and severity similar to prior liver injuries observed in thalassemia trials. The company said the drug’s benefit-risk profile remains unchanged. Agios mitapivat safety update
• Neutral Sentiment: The FDA’s new PDUFA goal date is February 1, 2027, compared with the original November 1, 2026 target. The decision will determine whether Agios can expand mitapivat into a potentially large sickle cell disease market of roughly 100,000 U.S. patients.
• Negative Sentiment: The FDA requested additional information to assess whether a Risk Evaluation and Mitigation Strategy (REMS) is needed. It classified Agios’ response as a major amendment, triggering a three-month review extension and delaying a potential approval, launch and related revenue opportunity. FDA extends Agios review
• Negative Sentiment: The potential REMS signals that liver-safety considerations remain part of the regulatory review and could add monitoring requirements or commercial friction if mitapivat is approved for sickle cell disease.
• Negative Sentiment: Recent insider activity showed Chief Medical Officer Sarah Gheuens selling 7,866 shares for approximately $296,470 under a pre-arranged Rule 10b5-1 plan. While scheduled sales do not necessarily indicate a change in outlook, the transaction adds a modest negative sentiment signal. Agios insider sale

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Bank of America increased their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a "buy" rating in a report on Monday, September 21st. TD Cowen upgraded Agios Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 24th. JPMorgan Chase & Co. raised their price target on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $55.00 price objective on the stock. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $41.50.

Agios Pharmaceuticals Price Performance

The company has a market capitalization of $1.83 billion, a P/E ratio of -4.36 and a beta of 0.63. The company's 50-day moving average price is $33.69 and its two-hundred day moving average price is $31.69.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The company had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. On average, analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sarah Gheuens sold 7,866 shares of the business's stock in a transaction on Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at $2,059,570.05. The trade was a 12.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 39,855 shares of company stock worth $1,285,512. Company insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Agios Pharmaceuticals in the third quarter valued at approximately $101,000. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of Agios Pharmaceuticals by 4.0% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company's stock valued at $960,000 after purchasing an additional 1,100 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 15.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,893 shares of the biopharmaceutical company's stock valued at $363,000 after purchasing an additional 1,428 shares in the last quarter. Inspire Investing LLC increased its stake in shares of Agios Pharmaceuticals by 4.7% in the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company's stock valued at $636,000 after purchasing an additional 861 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company's stock valued at $62,723,000 after purchasing an additional 1,782,457 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company's research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.